222 related articles for article (PubMed ID: 17458173)
1. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
Doehn C; Kausch I; Böhmer T; Sommerauer M; Jocham D
Curr Opin Mol Ther; 2007 Apr; 9(2):183-9. PubMed ID: 17458173
[TBL] [Abstract][Full Text] [Related]
2. Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
Morse MA
Curr Opin Mol Ther; 2001 Aug; 3(4):407-12. PubMed ID: 11525565
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.
DiPaola RS; Plante M; Kaufman H; Petrylak DP; Israeli R; Lattime E; Manson K; Schuetz T
J Transl Med; 2006 Jan; 4():1. PubMed ID: 16390546
[TBL] [Abstract][Full Text] [Related]
4. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM
J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798
[TBL] [Abstract][Full Text] [Related]
5. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
6. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
7. Technology evaluation: PROSTVAC, Therion.
Doehn C; Jocham D
Curr Opin Mol Ther; 2002 Oct; 4(5):528-34. PubMed ID: 12435056
[TBL] [Abstract][Full Text] [Related]
8. Technology evaluation: Onyvax-P, Onyvax.
Doehn C; Böhmer T; Jocham D
Curr Opin Mol Ther; 2005 Oct; 7(5):511-9. PubMed ID: 16248287
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Greiner JW; Zeytin H; Anver MR; Schlom J
Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
[TBL] [Abstract][Full Text] [Related]
11. Development of the PANVAC-VF vaccine for pancreatic cancer.
Petrulio CA; Kaufman HL
Expert Rev Vaccines; 2006 Feb; 5(1):9-19. PubMed ID: 16451103
[TBL] [Abstract][Full Text] [Related]
12. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
13. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
14. GVAX (Cell Genesys).
Dummer R
Curr Opin Investig Drugs; 2001 Jun; 2(6):844-8. PubMed ID: 11572668
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Hodge JW; Higgins J; Schlom J
Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
[TBL] [Abstract][Full Text] [Related]
16. Development of PROSTVAC immunotherapy in prostate cancer.
Singh P; Pal SK; Alex A; Agarwal N
Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic vaccines for prostate cancer.
Cha E; Fong L
Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
[TBL] [Abstract][Full Text] [Related]
18. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
Ertl HC
Curr Opin Mol Ther; 2002 Dec; 4(6):601-5. PubMed ID: 12596363
[TBL] [Abstract][Full Text] [Related]
19. A year of successful cancer vaccines points to a path forward.
Morse MA; Whelan M
Curr Opin Mol Ther; 2010 Feb; 12(1):11-3. PubMed ID: 20140811
[TBL] [Abstract][Full Text] [Related]
20. PSA-based vaccines for the treatment of prostate cancer.
Madan RA; Gulley JL; Arlen PM
Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
